John C. Reed
Executive Vice President of Innovative Medicine and R&DDr. John C. Reed, M.D., Ph.D., is Director of Madrigal Pharmaceuticals, Inc. since August 11, 2026. He is Chief Revenue Officer of Allied Microbiota Inc. Dr. Reed serves as Executive Vice President of Innovative Medicine, R&D of Johnson & Johnson since November 2023. He joined Johnson & Johnson in April 2023. He served as Executive Vice President of Pharmaceuticals, R&D of Johnson & Johnson since April 03, 2023 until November 2023. He had been an Executive Vice President and Global Head of Research & Development at Sanofi since July 2018 until February 10, 2023. He serves as an Assistant Professor of Department of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine. Dr. Reed is an Adjunct professor at the University of California San Diego (UCSD) Department of Molecular Pathology, University of Florida, University of Central Florida and in San Diego State University's Biology department. Dr. Reed co-founded IDUN Pharmaceuticals Inc., in 1993. He was the Global Head of Roche Pharma Research & Early Development (Pred) at Roche Holding AG since April 2, 2013 until 2018. He served as an Advisor and Consultant to Berlex Laboratories Inc., DAKO Inc., Genta Inc., PharMingen Inc., Rigel Pharmaceuticals Inc., Stratagene Inc., Abbott, Isis and other biotechnology and pharmaceutical companies, as well as Robertson Stephens investment bankers. Dr. Reed served as the President and Chief Executive Officer of Sanford-Burnham Medical Research Institute since January 2002. He joined Burnham Institute as Deputy Director of the Cancer Center beginning in 1994, as Scientific Director since 1995 and as Cancer Center Director since 2002 and also served as Director of Oncogene and Tumor Suppressor Gene Program. He has also served in various capacities as an Advisor to the National Cancer Institute, the American Association for Cancer Research (AACR) and American Cancer Society. From 1989 to 1992, he worked as Assistant Director, Laboratory of Molecular Diagnosis at the hospital of the University of Pennsylvania. He served as a Director of Stratagene Corporation since June 2004. He served as Director of Pharmion Corp., from June 2, 2005 to 2008. He served as a Member of Scientific Advisory Board at Predictive Biosciences, Inc. since May 2007. Dr. Reed has served on multiple editorial boards of research journals and was scientific founder or co-founder of four biotechnology companies. He served as Member of Advisory Board at Sanford-Burnham Medical Research Institute. He serves on the board of Directors of Stratagene Inc. and BIOCOM. He also serves as a Member of the Board of Trustees and Member of Scientific Advisory Board at The Burnham Institute. He served as Member of Scientific Advisory Board at Guava Technologies Inc. Dr. Reed served as a Director of ISIS Pharmaceuticals Inc., from February 2002 February 12, 2013. He served as a Director of Repros Therapeutics Inc. from September 29, 2008 to November 1, 2009. He served as a Director of Clovis Oncology, Inc. until February 14, 2013. He began his academic career as a member of the faculty at the University of Pennsylvania in 1988 and subsequently held faculty appointment at ETH-Zurich. He served as a Director of IDUN Pharmaceuticals, Inc. and Sanford-Burnham Medical Research Institute. In 1992, he joined the Sanford-Burnham Medical Research Institute in La Jolla, California. He served as a Member of the Scientific Advisory Board at IDUN Pharmaceuticals, Inc. He served as a Member of Scientific Advisory Board at Cengent Therapeutics Inc. Dr. Reed is an associate member of UCSD's Cancer Center. He serves on the Editorial boards of over 12 scientific journals. Dr. Reed is the 2003 recipient of the Bristol-Myers-Squibb unrestricted grant for distinguished cancer research. According to the Institute for Scientific Information, Dr. Reed has published more papers related to apoptosis and has received more citations for his publications than any other scientist in the world. He is the Author of approximately 600 peer-reviewed scientific articles and nearly 75 book chapters. From 2002 to 2013, he served as CEO of the Institute. During his tenure, he ran a highly productive laboratory that generated more than 900 research publications and over 130 patents, was awarded more than 100 research grants and trained over 100 post-doctoral fellows. He is a Fellow of the American Association for the Advancement of Science (AAAS) and the recipient of numerous honors and awards for his accomplishments in biomedical research. He was also a postdoctoral fellow in molecular biology at the Wistar Institute of Anatomy and Biology. Dr. Reed holds a B.A. in chemistry from the University of Virginia, Charlottesville and an M.D. and a Ph.D. in Immunology from the University of Pennsylvania School of Medicine in 1986, where he also received his clinical and postdoctoral training.
Positions
- Company NameJohnson & JohnsonStock CodeJNJPositionExecutive Vice President of Innovative Medicine and R&DColleagues
- JDJoaquin DuatoCEO & Chairman
- JJJoseph James WolkExecutive VP & CFO
- TSTimothy SchmidExecutive VP & Worldwide Chairman of MedTech
- RJRobert J. DeckerController & Chief Accounting Officer
- MAMarillyn A. HewsonLead Independent Director
- HJHubert JolyIndependent Director
- MAMark Alan WeinbergerIndependent Director
- EAEugene A. WoodsIndependent Director
